CAR T-cell cancer therapy / Orion Corp - LARVOL DELTA

Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy (GlobeNewswire) - "Orion Corporation and the Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy...In CAR T-cell therapy, the patient's own white blood cells are genetically modified to attack the cancer and kill it. CAR T-cells are currently used to treat certain haematological cancers."

Licensing / partnership • Hematological Malignancies • Oncology